Archives
-
KN-62: Mechanism, Evidence and Scope
2026-10-15
KN-62, also known as 1-[N,O-bis-(5-isoquinolinesulphonyl)-N-methyl-L-tyrosy]-4-phenylpiperazine, is listed by APExBIO as a CaMKII inhibitor for research. The product information describes calmodulin-site binding, a reported Ki of 0.9 μM, and effects on secretion, glucose transport, and K562-cell proliferation. Because no identity-matched primary paper is available here, these claims should be treated as supplier-documented rather than independently verified findings.
-
WM-8014: Mechanism and Evidence Boundaries
2026-10-15
A source-attributed overview of WM-8014 as a reported reversible KAT6A/KAT6B inhibitor, distinguishing biochemical mechanism, cellular and zebrafish observations, and the limits imposed by the absence of identity-matched primary research evidence.
-
WM-8014: What Its Product Evidence Supports
2026-10-14
APExBIO describes WM-8014 as a reversible, competitive inhibitor of the MYST-family acetyltransferases KAT6A and KAT6B, with weaker activity reported against KAT5 and KAT7. The product information links this biochemical activity to cell-cycle arrest and senescence-associated observations in mouse embryonic fibroblasts and to reduced proliferation in a KRAS G12V zebrafish liver model. These findings provide a plausible mechanistic framework, but the available documentation does not provide identity-matched primary-study details, effect sizes, sample sizes, uncertainty estimates, or evidence sufficient to establish target exclusivity or translational efficacy.
-
QPRT, P2Y11 Signaling and Breast Cancer Invasion
2026-10-14
Liu and colleagues report that QPRT is associated with invasive breast cancer behavior and propose a pathway linking QPRT to P2Y11-related purinergic signaling, Rho–ROCK/PLC signaling, myosin light-chain phosphorylation, and cell invasion. The evidence is mechanistic and preclinical: it relies on breast cancer cell models, pharmacological perturbation, and a transgenic mouse model rather than clinical treatment outcomes.
-
Canagliflozin and Renal Mitochondrial Remodeling
2026-10-13
A 2025 mouse study examined whether Canagliflozin’s kidney-protective effects extend beyond glucose lowering to proximal-tubule mitochondrial structure and function. The reported improvements were stronger in males than females, supporting mitochondrial remodeling as a plausible mechanism while leaving causality, durability, and human applicability unresolved.
-
Erlotinib and CXCR4–EGFR Signaling
2026-10-13
Recent work indicates that CXCR4 and EGFR can assemble into ligand-responsive signaling complexes, adding receptor context to the interpretation of EGFR pathway biology. Erlotinib is relevant as an EGFR kinase inhibitor, but the supplied study does not test Erlotinib or establish that kinase inhibition disrupts CXCR4–EGFR complex formation.
-
PPM1D, p38 Signaling and Renal Pyroptosis
2026-10-12
A preclinical study links increased WIP1/PPM1D activity with restraint of p38-associated renal tubular pyroptosis in sepsis-related acute kidney injury models, while emphasizing the limits of pharmacological and model-based inference.
-
What the RESTRICT-seq Preprint Establishes
2026-10-12
The supplied record supports a cautious interpretation of RESTRICT-seq as a time-aware CRISPR-screening framework aimed at identifying epigenetic dependencies associated with SCC resistance. It does not provide enough study-specific data to assess individual hits, effect sizes, validation experiments, or whether WM-8014 was used. The preprint status also limits the strength of current conclusions.
-
Cefodizime Beyond Spectrum: A Translational Framework
2026-10-10
Cefodizime is more than a broad-spectrum label: its PBP biology, supplier-reported antibacterial profile, and potential immunomodulatory relevance create a framework for translational research. This article separates established findings from hypotheses, positions cefodizime against historical Gram-negative benchmarks, and outlines evidence-led questions without substituting for clinical guidance or laboratory protocols.
-
Purmorphamine and the Translational Logic of Smo
2026-10-09
A source-grounded perspective on Purmorphamine as a Smoothened agonist, connecting Hedgehog biology with osteogenic research, sensory signaling, translational study design, and the boundaries of cross-species interpretation.
-
Microplastics, Pulmonary Fibrosis, and Immunodetection
2026-10-09
A source-grounded overview of reported pulmonary effects from microplastics and nanoplastics, with emphasis on polymer- and size-dependent toxicity, the proposed FXR–YAP1 pathway, and the evidentiary role and limitations of HRP-based immunodetection of goat primary antibodies.
-
Annexin V-Cy5/DAPI Apoptosis Kit: Reading Cell Fate
2026-10-08
The Annexin V-Cy5/DAPI Apoptosis Kit provides a two-signal framework for interpreting phosphatidylserine exposure alongside membrane integrity. This article connects that cell apoptosis assay to the P2RX1–CaMKII–PI3K/Akt findings in Ph+ ALL while clarifying evidence limits and biological interpretation.
-
Angiotensin Peptides and SARS-CoV-2 Spike Binding
2026-10-08
A 2025 study found that naturally occurring angiotensin fragments can enhance SARS-CoV-2 spike-protein binding to host receptors, with particularly strong effects in the spike–AXL interaction. Its structure–activity comparisons connect renin-angiotensin system research with viral receptor biology, while the antibody-based assay design means the findings remain biochemical and hypothesis-generating rather than clinical evidence.
-
Temafloxacin Through an Evidence-Interpretation Lens
2026-10-07
Temafloxacin is examined as a fluoroquinolone broad-spectrum antibacterial agent through mechanism, susceptibility, pharmacokinetic, and evidence-quality perspectives. This article connects the landmark 1989 study with modern research interpretation while clarifying applicability limits for antibacterial and intracellular models.
-
WM-8014: KAT6A Inhibitor Evidence Guide
2026-10-07
WM-8014 is a supplier-described reversible, competitive KAT6A inhibitor with reported activity against KAT6B, KAT5, and KAT7. Available evidence supports its use as a mechanistic research probe for senescence and cell-cycle studies, but it does not establish clinical efficacy or broad translational validity.